Charles Schwab
STOK icon

Charles Schwab’s Stoke Therapeutics STOK Stock Holding History

Charles Schwab’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
467,012
+29,837
+7% +$958K ﹤0.01% 1956
2026
Q1 		$14.2M Buy
437,175
+26,269
+6% +$862K ﹤0.01% 1930
2025
Q4 		$13M Buy
410,906
+7,997
+2% +$240K ﹤0.01% 1998
2025
Q3 		$9.47M Buy
402,909
+62,130
+18% +$1.06M ﹤0.01% 2147
2025
Q2 		$3.87M Buy
340,779
+30,472
+10% +$289K ﹤0.01% 2440
2025
Q1 		$2.06M Sell
310,307
-31,822
-9% -$297K ﹤0.01% 2609
2024
Q4 		$3.77M Buy
342,129
+25,995
+8% +$319K ﹤0.01% 2471
2024
Q3 		$3.89M Buy
316,134
+26,870
+9% +$381K ﹤0.01% 2492
2024
Q2 		$3.91M Buy
289,264
+66,226
+30% +$894K ﹤0.01% 2453
2024
Q1 		$3.01M Buy
223,038
+17,796
+9% +$108K ﹤0.01% 2476
2023
Q4 		$1.08M Sell
205,242
-12,097
-6% -$51.7K ﹤0.01% 2801
2023
Q3 		$856K Buy
217,339
+10,448
+5% +$68.7K ﹤0.01% 2848
2023
Q2 		$2.2M Buy
206,891
+43,176
+26% +$459K ﹤0.01% 2515
2023
Q1 		$1.36M Sell
163,715
-1,147
-0.7% -$10.3K ﹤0.01% 2632
2022
Q4 		$1.52M Buy
164,862
+2,617
+2% +$27.2K ﹤0.01% 2644
2022
Q3 		$2.08M Sell
162,245
-3,375
-2% -$53.8K ﹤0.01% 2575
2022
Q2 		$2.19M Buy
165,620
+14,888
+10% +$226K ﹤0.01% 2544
2022
Q1 		$3.17M Buy
150,732
+2,952
+2% +$59.1K ﹤0.01% 2485
2021
Q4 		$3.55M Buy
147,780
+1,783
+1% +$42.5K ﹤0.01% 2523
2021
Q3 		$3.71M Buy
145,997
+9,375
+7% +$261K ﹤0.01% 2509
2021
Q2 		$4.6M Buy
136,622
+14,262
+12% +$504K ﹤0.01% 2392
2021
Q1 		$4.75M Buy
122,360
+6,363
+5% +$362K ﹤0.01% 2328
2020
Q4 		$7.18M Buy
115,997
+22,238
+24% +$1.02M ﹤0.01% 2046
2020
Q3 		$3.14M Buy
93,759
+29,868
+47% +$853K ﹤0.01% 2308
2020
Q2 		$1.52M Sell
63,891
-6,512
-9% -$155K ﹤0.01% 2507
2020
Q1 		$1.61M Buy
70,403
+17,503
+33% +$432K ﹤0.01% 2351
2019
Q4 		$1.5M Buy
52,900
+546
+1% +$13.7K ﹤0.01% 2487
2019
Q3 		$1.13M Buy
+52,354
New +$1.46M ﹤0.01% 2534

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's STOK Position: Q2 2026 in Review

Charles Schwab increased its Stoke Therapeutics (STOK) stake by 6.8% in Q2 2026, buying an estimated $958K and bringing the position to 467,012 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1956.

Charles Schwab first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Charles Schwab held 467,012 shares of Stoke Therapeutics worth $15.3M as of Q2 2026.
  • Charles Schwab bought 29,837 Stoke Therapeutics shares in Q2 2026, an estimated $958K.
  • Stoke Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1956 holding.
  • Charles Schwab first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.